Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma

The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of cancer therapy in recent years, which have changed the landscape of cancer treatment. In the field of HCC treatment, this c...

Full description

Saved in:
Bibliographic Details
Published in:Immunology 2024-05, Vol.172 (1), p.21-45
Main Authors: Chen, Xiu, Kou, Liqiu, Xie, Xiaolu, Su, Song, Li, Jun, Li, Yaling
Format: Article
Language:English
Subjects:
Bevacizumab
Biomarkers
Cancer
Cancer therapies
Drugs
Effectiveness
Hepatocellular carcinoma
Immune checkpoint inhibitors
Immune system
Immunosuppressive agents
Inhibitors
Sensitivity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The treatment of hepatocellular carcinoma (HCC), particularly advanced HCC, has been a serious challenge. Immune checkpoint inhibitors (ICIs) are landmark drugs in the field of cancer therapy in recent years, which have changed the landscape of cancer treatment. In the field of HCC treatment, this class of drugs has shown good therapeutic prospects. For example, atezolizumab in combination with bevacizumab has been approved as first-line treatment for advanced HCC due to significant efficacy. However, sensitivity to ICI therapy varies widely among HCC patients. Therefore, there is an urgent need to search for determinants of resistance/sensitivity to ICIs and to screen biomarkers that can predict the efficacy of ICIs. This manuscript reviews the research progress of prognostic biomarkers associated with ICIs in HCC in order to provide a scientific basis for the development of clinically individualised precision medication regimens.
ISSN:0019-2805
1365-2567
DOI:10.1111/imm.13751